Trial Profile
Intra-nasal Naloxone for Treatment of Impaired Awareness of Hypoglycemia
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 29 Mar 2023
Price :
$35
*
At a glance
- Drugs Naloxone (Primary)
- Indications Cocaine-related disorders; Eating disorders; Opioid-related disorders; Substance-related disorders
- Focus Pharmacodynamics
- 02 Jul 2021 Status changed from active, no longer recruiting to discontinued.
- 16 Jan 2020 Planned End Date changed from 1 Dec 2019 to 1 Dec 2021.
- 16 Jan 2020 Planned primary completion date changed from 1 Nov 2019 to 1 Nov 2021.